Squarepoint
ANTX icon

Squarepoint’s AN2 Therapeutics ANTX Stock Holding History

Squarepoint’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-61,612
Closed -$70.2K – 4230
2025
Q4 		$70.2K Sell
61,612
-2,655
-4% -$3.1K ﹤0.01% 4090
2025
Q3 		$81.6K Buy
64,267
+54,205
+539% +$62K ﹤0.01% 4151
2025
Q2 		$10.7K Buy
+10,062
New +$12K ﹤0.01% 4410
2025
Q1 		– Sell
-62,441
Closed -$86.2K – 4526
2024
Q4 		$86.2K Buy
+62,441
New +$75.7K ﹤0.01% 4733
2024
Q3 		– Sell
-97,063
Closed -$209K – 4078
2024
Q2 		$209K Buy
97,063
+47,456
+96% +$113K ﹤0.01% 3636
2024
Q1 		$161K Buy
+49,607
New +$540K ﹤0.01% 3685

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Squarepoint's ANTX Position: Q1 2026 in Review

Squarepoint sold out of AN2 Therapeutics (ANTX) in Q1 2026, closing a stake of 61,612 shares — an estimated $70.2K sold.

Squarepoint first reported a position in ANTX in Q1 2024 and held it in 6 quarters. The position peaked at $209K in Q2 2024. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Squarepoint reported no remaining AN2 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 61,612 AN2 Therapeutics shares in Q1 2026, an estimated $70.2K.
  • Squarepoint first reported a position in AN2 Therapeutics in Q1 2024 and held it in 6 quarters.
  • Squarepoint's AN2 Therapeutics position peaked at $209K in Q2 2024.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.